CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Inovio Pharmaceuticals, Inc. - INO CFD

    0.3708
    2.74%
    0.0400
    Low: 0.3536
    High: 0.3762
    Market Trading Hours* (UTC) Opens on Friday at 14:30

    Mon - Fri: 14:30 - 21:00

    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.0400
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026207 %
    Charges from full value of position ($-4.98)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026207%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003985 %
    Charges from full value of position ($0.76)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003985%
    Overnight fee time 22:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Inovio Pharmaceuticals Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 0.3609
    Open* 0.3536
    1-Year Change* -81.39%
    Day's Range* 0.3536 - 0.3762
    52 wk Range 0.32-2.12
    Average Volume (10 days) 2.23M
    Average Volume (3 months) 74.04M
    Market Cap 114.16M
    P/E Ratio -100.00K
    Shares Outstanding 272.99M
    Revenue 854.03K
    EPS -0.64
    Dividend (Yield %) N/A
    Beta 1.02
    Next Earnings Date Feb 28, 2024

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Nov 30, 2023 0.3708 0.0096 2.66% 0.3612 0.3765 0.3530
    Nov 29, 2023 0.3609 -0.0132 -3.53% 0.3741 0.3855 0.3553
    Nov 28, 2023 0.3807 -0.0222 -5.51% 0.4029 0.4029 0.3670
    Nov 27, 2023 0.3925 0.0023 0.59% 0.3902 0.4053 0.3875
    Nov 24, 2023 0.3989 0.0162 4.23% 0.3827 0.3989 0.3827
    Nov 22, 2023 0.3889 -0.0003 -0.08% 0.3892 0.3947 0.3808
    Nov 21, 2023 0.3882 -0.0093 -2.34% 0.3975 0.3975 0.3813
    Nov 20, 2023 0.3970 0.0040 1.02% 0.3930 0.4018 0.3815
    Nov 17, 2023 0.4086 0.0151 3.84% 0.3935 0.4098 0.3815
    Nov 16, 2023 0.3872 0.0122 3.25% 0.3750 0.4068 0.3649
    Nov 15, 2023 0.3650 0.0173 4.98% 0.3477 0.3764 0.3477
    Nov 14, 2023 0.3529 0.0079 2.29% 0.3450 0.3626 0.3422
    Nov 13, 2023 0.3349 0.0051 1.55% 0.3298 0.3349 0.3293
    Nov 10, 2023 0.3283 -0.0162 -4.70% 0.3445 0.3445 0.3138
    Nov 9, 2023 0.3359 -0.0191 -5.38% 0.3550 0.3550 0.3335
    Nov 8, 2023 0.3526 -0.0139 -3.79% 0.3665 0.3665 0.3421
    Nov 7, 2023 0.3624 -0.0048 -1.31% 0.3672 0.3742 0.3611
    Nov 6, 2023 0.3750 -0.0099 -2.57% 0.3849 0.3858 0.3670
    Nov 3, 2023 0.3823 0.0153 4.17% 0.3670 0.4120 0.3664
    Nov 2, 2023 0.3753 0.0373 11.04% 0.3380 0.3783 0.3374

    Inovio Pharmaceuticals, Inc. Events

    Time (UTC) Country Event
    Wednesday, February 28, 2024

    Time (UTC)

    10:59

    Country

    US

    Event

    Q4 2023 Inovio Pharmaceuticals Inc Earnings Release
    Q4 2023 Inovio Pharmaceuticals Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 10.2623 1.77476 7.41122 4.11193 30.4819
    Revenue 10.2623 1.77476 7.41122 4.11193 30.4819
    Total Operating Expense 277.836 302.993 126.787 115.22 124.573
    Selling/General/Admin. Expenses, Total 90.1853 53.7523 37.2478 27.2032 29.3152
    Research & Development 187.65 249.24 94.2454 88.0173 95.2579
    Unusual Expense (Income) 0 0 -4.70606 0 0
    Operating Income -267.574 -301.218 -119.376 -111.109 -94.0911
    Interest Income (Expense), Net Non-Operating -6.21775 -2.34978 -42.8094 -10.1968 -0.70688
    Net Income Before Taxes -277.653 -303.224 -162.89 -120.809 -94.798
    Net Income After Taxes -277.653 -303.224 -162.89 -120.552 -96.9678
    Minority Interest 0 0 1.06376 1.19256
    Net Income Before Extra. Items -279.818 -303.659 -166.411 -119.359 -96.9678
    Net Income -279.818 -303.659 -166.411 -119.359 -96.9678
    Income Available to Common Excl. Extra. Items -279.818 -303.659 -166.411 -119.359 -96.9678
    Income Available to Common Incl. Extra. Items -279.818 -303.659 -166.411 -119.359 -96.9678
    Diluted Net Income -279.818 -303.659 -166.411 -119.359 -96.9678
    Diluted Weighted Average Shares 238.622 208.83 155.127 98.718 92.54
    Diluted EPS Excluding Extraordinary Items -1.17264 -1.4541 -1.07274 -1.20909 -1.04785
    Diluted Normalized EPS -1.17264 -1.4541 -1.10308 -1.20909 -1.04785
    Total Extraordinary Items
    Other, Net -3.86158 0.34337 -0.7049 0.4962
    Equity In Affiliates -2.16521 -0.43439 -4.58461
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 0.22597 0.11494 0.12467 9.15413 0.7844
    Revenue 0.22597 0.11494 0.12467 9.15413 0.7844
    Total Operating Expense 37.2671 44.0671 56.0708 44.9112 104.922
    Selling/General/Admin. Expenses, Total 13.5231 13.8906 13.9509 11.824 48.4568
    Research & Development 21.744 30.1765 42.1199 33.0871 56.4649
    Operating Income -37.0411 -43.9522 -55.9462 -35.757 -104.137
    Interest Income (Expense), Net Non-Operating 2.93443 5.72854 4.2473 -1.08608 -4.35694
    Other, Net -1.42787 -2.42568 -2.76429 -0.94078 -0.00305
    Net Income Before Taxes -35.5345 -40.6493 -54.4631 -37.7839 -108.497
    Net Income After Taxes -35.5345 -40.6493 -54.4631 -37.7839 -108.497
    Minority Interest 0
    Equity In Affiliates 0 0 0 0 0
    Net Income Before Extra. Items -35.5345 -40.6493 -54.4631 -37.7839 -108.497
    Net Income -35.5345 -40.6493 -54.4631 -37.7839 -108.497
    Income Available to Common Excl. Extra. Items -35.5345 -40.6493 -54.4631 -37.7839 -108.497
    Income Available to Common Incl. Extra. Items -35.5345 -40.6493 -54.4631 -37.7839 -108.497
    Diluted Net Income -35.5345 -40.6493 -54.4631 -37.7839 -108.497
    Diluted Weighted Average Shares 264.354 258.438 250.585 249.351 235.278
    Diluted EPS Excluding Extraordinary Items -0.13442 -0.15729 -0.21734 -0.15153 -0.46114
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -0.12685 -0.15729 -0.21734 -0.15153 -0.46114
    Unusual Expense (Income) 2 0
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 315.243 448.445 471.171 94.201 87.8148
    Cash and Short Term Investments 252.999 401.315 411.643 89.5341 81.2325
    Cash & Equivalents 46.3294 71.1438 250.728 22.1961 23.6936
    Short Term Investments 206.669 330.171 160.915 67.338 57.5388
    Total Receivables, Net 11.7382 8.03204 19.0637 2.03212 4.05494
    Accounts Receivable - Trade, Net 1.70173 5.46685 18.56 0.70007 3.31636
    Prepaid Expenses 50.5057 39.0982 40.4639 2.63474 2.5274
    Total Assets 348.533 495.941 539.772 143.952 131.113
    Property/Plant/Equipment, Total - Net 17.9562 29.0242 24.0894 26.556 15.949
    Property/Plant/Equipment, Total - Gross 39.5196 47.9686 40.083 39.7225 25.9489
    Accumulated Depreciation, Total -21.5634 -18.9444 -15.9936 -13.1665 -9.99992
    Goodwill, Net 10.5134 10.5134 10.5134 10.5134 10.5134
    Intangibles, Net 2.12986 2.62636 3.14677 3.69385 4.76015
    Long Term Investments 2.00714 3.9068 4.89475 6.31536 9.40591
    Other Long Term Assets, Total 0.68404 1.42579 25.9575 2.67202 2.67
    Total Current Liabilities 96.8681 65.7416 41.706 31.9893 35.2998
    Accounts Payable 19.8625 24.2137 0.82552 6.91908 10.0438
    Payable/Accrued 45.2204 0.54803 0.64297 0.72973 4.60189
    Accrued Expenses 29.2224 36.3611 32.658 17.4428 15.1386
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 2.5627 4.61885 7.57944 6.89777 5.51547
    Total Liabilities 126.171 96.2721 78.6317 140.516 44.1771
    Total Long Term Debt 16.6148 14.9597 18.6558 77.0229 0
    Deferred Income Tax 0.03205 0.03205 0.03205 0.03205 0.02477
    Minority Interest 0 1.96976 0.09627
    Other Liabilities, Total 12.6556 15.5387 18.2379 29.5025 8.75633
    Total Equity 222.363 399.669 461.141 3.4351 86.9361
    Preferred Stock - Non Redeemable, Net 0 0 0 0 0
    Common Stock 0.25309 0.21738 0.18685 0.10136 0.09723
    Additional Paid-In Capital 1710.66 1609.59 1367.41 742.647 707.794
    Retained Earnings (Accumulated Deficit) -1487.85 -1209.86 -906.197 -739.786 -620.426
    Other Equity, Total -0.69874 -0.28224 -0.25615 0.47261 -0.52887
    Total Liabilities & Shareholders’ Equity 348.533 495.941 539.772 143.952 131.113
    Total Common Shares Outstanding 253.091 217.383 186.851 101.361 97.2258
    Total Preferred Shares Outstanding 0.00001 0.00001 0.00001 0.00002 0.00002
    Long Term Debt 16.6148 14.9597 18.6558 77.0229
    Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
    Total Current Assets 174.767 203.284 233.896 315.243 350.208
    Cash and Short Term Investments 167.473 194.925 223.751 252.999 281.883
    Cash & Equivalents 18.8046 52.7125 28.2381 46.3294 21.9882
    Short Term Investments 148.669 142.213 195.513 206.669 259.895
    Total Receivables, Net 2.14393 5.11623 5.03511 11.7382 10.0807
    Accounts Receivable - Trade, Net 0 0.00595 0.0733 1.70173 2.44287
    Prepaid Expenses 5.1498 3.24281 5.11017 50.5057 58.2442
    Total Assets 193.097 233.038 266.583 348.533 391.968
    Property/Plant/Equipment, Total - Net 14.7298 15.7927 16.8489 17.9562 26.1652
    Goodwill, Net 0 10.5134 10.5134 10.5134 10.5134
    Intangibles, Net 0 0 2.04778 2.12986 2.24944
    Long Term Investments 2.9949 2.78053 2.62378 2.00714 2.12999
    Other Long Term Assets, Total 0.60532 0.66689 0.65252 0.68404 0.70199
    Total Current Liabilities 43.711 51.9323 55.1511 96.8681 94.9147
    Payable/Accrued 0.71172 1.68638 1.41727 80.9073 75.7816
    Accrued Expenses 19.4909 21.1189 21.9336 13.3981 16.3067
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 3.82808 3.74862 4.211 2.5627 2.82645
    Total Liabilities 54.9375 63.6664 67.369 126.171 125.271
    Total Long Term Debt 0 0 0 16.6148 16.3013
    Long Term Debt 0 0 0 16.6148 16.3013
    Deferred Income Tax 0.03205 0.03205 0.03205 0.03205 0.03205
    Other Liabilities, Total 11.1944 11.702 12.1859 12.6556 14.0227
    Total Equity 138.16 169.372 199.214 222.363 266.697
    Preferred Stock - Non Redeemable, Net 0 0 0 0 0
    Common Stock 0.26973 0.26807 0.26274 0.25309 0.24948
    Additional Paid-In Capital 1736.6 1733.83 1728.03 1710.66 1700.72
    Retained Earnings (Accumulated Deficit) -1597.96 -1564.03 -1528.5 -1487.85 -1433.38
    Other Equity, Total -0.75107 -0.69126 -0.5828 -0.69874 -0.88521
    Total Liabilities & Shareholders’ Equity 193.097 233.038 266.583 348.533 391.968
    Total Common Shares Outstanding 269.731 268.073 262.739 253.091 249.485
    Total Preferred Shares Outstanding 0.00001 0.00001 0.00001 0.00001 0.00001
    Accounts Payable 3.19205 8.67007 11.1944
    Current Port. of LT Debt/Capital Leases 16.4883 16.7083 16.3948
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -279.818 -303.659 -167.475 -120.552 -96.9678
    Cash From Operating Activities -216.215 -215.709 -177.979 -97.8501 -73.5502
    Cash From Operating Activities 3.65671 3.0401 3.039 3.59839 3.74718
    Amortization 0.49649 0.52042 0.54708 1.06629 1.24958
    Deferred Taxes 0 0 0.0054 0
    Non-Cash Items 39.6153 34.0382 56.9816 21.5747 13.3131
    Changes in Working Capital 19.8342 50.3515 -71.0718 -3.54312 5.10778
    Cash From Investing Activities 109.586 -175.344 -58.7957 -9.045 42.4199
    Capital Expenditures -0.96915 -1.23101 -1.52067 -0.98793 -2.08502
    Other Investing Cash Flow Items, Total 110.555 -174.113 -57.2751 -8.05707 44.5049
    Cash From Financing Activities 81.8407 211.499 465.28 105.398 31.0373
    Financing Cash Flow Items 0 0 2.37997 -0.35463 0
    Issuance (Retirement) of Stock, Net 81.8407 211.499 462.728 8.3086 31.0373
    Foreign Exchange Effects -0.02556 -0.03013 0.02721
    Net Change in Cash -24.8144 -179.584 228.532 -1.49754 -0.09295
    Cash Interest Paid 1.06698 1.0778 4.62476 2.71759
    Issuance (Retirement) of Debt, Net 0 0 0.17162 97.4436
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -40.6493 -279.818 -225.355 -187.571 -79.0737
    Cash From Operating Activities -36.6645 -216.215 -179.875 -112.41 -61.8821
    Cash From Operating Activities 0.70738 3.65671 2.77667 1.86996 0.92938
    Amortization 0.08208 0.49649 0.37691 0.25733 0.12677
    Non-Cash Items 1.7177 39.6153 35.4049 29.4844 15.7913
    Cash Interest Paid 0.53349 1.06698 1.06698 0.53349 0.53349
    Changes in Working Capital 1.47767 19.8342 6.92106 43.5492 0.3442
    Cash From Investing Activities 18.9999 109.586 55.585 11.0283 21.3323
    Capital Expenditures -0.29698 -0.96915 -0.80404 -0.71721 0
    Other Investing Cash Flow Items, Total 19.2969 110.555 56.3891 11.7456 21.3323
    Cash From Financing Activities -0.4247 81.8407 75.1727 71.3612 28.422
    Financing Cash Flow Items 0
    Issuance (Retirement) of Stock, Net -0.4247 81.8407 75.1727 71.3612 28.422
    Foreign Exchange Effects -0.00192 -0.02556 -0.0379 -0.02134 -0.00656
    Net Change in Cash -18.0912 -24.8144 -49.1555 -30.0419 -12.1343
    Issuance (Retirement) of Debt, Net 0
    Deferred Taxes
    Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
    The Vanguard Group, Inc. Investment Advisor/Hedge Fund 7.4859 20067883 1833565 2023-06-30 LOW
    D. E. Shaw & Co., L.P. Hedge Fund 2.8358 7602133 983289 2023-06-30 MED
    BlackRock Institutional Trust Company, N.A. Investment Advisor 2.2258 5966835 -13954601 2023-06-30 LOW
    Renaissance Technologies LLC Hedge Fund 2.0279 5436281 2795981 2023-06-30 HIGH
    Millennium Management LLC Hedge Fund 1.9921 5340253 5340253 2023-06-30 HIGH
    Jane Street Capital, L.L.C. Research Firm 1.1922 3196081 2261961 2023-06-30 HIGH
    JPMorgan Asset Management U.K. Limited Investment Advisor/Hedge Fund 1.1191 3000096 -64550 2023-06-30 LOW
    Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.0673 2861243 -2315538 2023-06-30 LOW
    Two Sigma Investments, LP Hedge Fund 0.8909 2388228 2367628 2023-06-30 HIGH
    Kim (Jong Joseph Ph.D.) Individual Investor 0.8751 2346000 0 2023-03-17 LOW
    Jacobs Levy Equity Management, Inc. Investment Advisor/Hedge Fund 0.801 2147319 969218 2023-06-30 MED
    GMT Capital Corp. Hedge Fund 0.5646 1513500 1513500 2023-06-30 LOW
    Charles Schwab Investment Management, Inc. Investment Advisor 0.4704 1260963 -501449 2023-06-30 LOW
    Qube Research & Technologies Ltd Hedge Fund 0.3522 944190 549920 2023-06-30 HIGH
    Weiner (David B) Individual Investor 0.3466 929124 19000 2023-05-16 LOW
    State Street Global Advisors (US) Investment Advisor/Hedge Fund 0.3273 877447 -27034933 2023-06-30 LOW
    Susquehanna International Group, LLP Investment Advisor 0.2825 757413 -115730 2023-06-30 MED
    BofA Global Research (US) Research Firm 0.2499 669960 -2850667 2023-06-30 LOW
    Y-Intercept (Hong Kong) Ltd Investment Advisor 0.2364 633613 633613 2023-06-30 HIGH
    Green Alpha Advisors, LLC Investment Advisor 0.2126 570049 387752 2023-09-30 LOW

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Inovio Pharmaceuticals Company profile

    Inovio Pharmaceuticals, Inc., a late-stage biotechnology company, focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system''s tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. The company is involved in conducting and planning clinical studies of its proprietary SynCon immunotherapies for human papillomavirus-caused pre-cancers and cancers; glioblastoma multiforme; hepatitis B virus; hepatitis C virus; human immunodeficiency virus; Ebola virus; middle east respiratory syndrome; and Zika virus. Its partners and collaborators include The Wistar Institute; University of Pennsylvania; GeneOne Life Science Inc.; ApolloBio Corporation; Regeneron Pharmaceuticals, Inc.; Genentech, Inc.; Plumbline Life Sciences, Inc.; Drexel University; National Institute of Allergy and Infectious Diseases; United States Military HIV Research Program; U.S. Army Medical Research Institute of Infectious Diseases; National Institutes of Health; HIV Vaccines Trial Network; Defense Advanced Research Projects Agency; the Parker Institute for Cancer Immunotherapy; QIAGEN N.V.; Coalition for Epidemic Preparedness Innovations; and Beijing Advaccine Biotechnology Co. Inovio Pharmaceuticals, Inc. was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.
    Industry: Biotechnology & Medical Research (NEC)

    6769 Mesa Ridge Rd.
    SAN DIEGO
    CALIFORNIA 92121
    US

    Income Statement

    • Annual
    • Quarterly

    News

    Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

    EZ PI expected to drop further but speed of decline

    08:16, 29 November 2023

    A weaker Dollar drives gold higher

    Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

    13:49, 28 November 2023

    Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

    US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

    13:20, 28 November 2023

    RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

    The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

    13:04, 28 November 2023

    Crude prices slide on OPEC+ uncertainty

    Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

    12:55, 28 November 2023
    GBP

    UK AUTUMN BUDGET: Will Hunt cut taxes? How will GBP react this time around?

    UK Chancellor Hunt will deliver the 2023 autumn statement to MPs on Wednesday 22 November.

    10:48, 21 November 2023

    Gold Rises as Traders price-in Fed Rate Cuts

    Gold prices have declined despite a drop in Treasury yields and a weaker US Dollar. We look at the key drivers and technical levels for the gold price.

    13:17, 20 November 2023

    People also watch

    Gold

    2,046.41 Price
    +0.480% 1D Chg, %
    Long position overnight fee -0.0196%
    Short position overnight fee 0.0114%
    Overnight fee time 22:00 (UTC)
    Spread 0.50

    US100

    15,956.60 Price
    +0.220% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0040%
    Overnight fee time 22:00 (UTC)
    Spread 1.8

    Oil - Crude

    75.75 Price
    +0.130% 1D Chg, %
    Long position overnight fee -0.0165%
    Short position overnight fee -0.0054%
    Overnight fee time 22:00 (UTC)
    Spread 0.030

    XRP/USD

    0.62 Price
    +0.690% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 22:00 (UTC)
    Spread 0.01168

    Still looking for a broker you can trust?

    Join the 570.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading